The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …

The NCCN Soft Tissue Sarcoma Guidelines include a subsection about treatment
recommendations for gastrointestinal stromal tumors (GISTs). The standard of practice …

In the past decade, many tyrosine-kinase inhibitors have been introduced in oncology and
haemato-oncology. Because this new class of drugs is extensively used, serious drug–drug …

Imatinib is a potent and selective inhibitor of the protein tyrosine kinase Bcr-Abl, platelet-
derived growth factor receptors (PDGFRα and PDGFRβ) and KIT. Imatinib is approved for …

In the recent years, eight tyrosine kinase inhibitors (TKIs) have been approved for cancer
treatment and numerous are under investigation. These drugs are rationally designed to …

Background Cancer patients receive numerous medications, including antineoplastic
agents, drugs for supportive care, and medications for comorbid illnesses. Therefore, they …

Several cancer treatments are shifting from traditional, time-limited, nonspecific cytotoxic
chemotherapy cycles to continuous oral treatment with specific protein-targeted therapies. In …

Imatinib, nilotinib, and dasatinib are tyrosine kinase inhibitors (TKIs) that have become first-
line treatments for Philadelphia chromosome-positive chronic myeloid leukemia (CML) …

1. INTRODUCTION Cytochrome P450s (CYPs) constitute a superfamily of hemecontaining
enzymes that catalyze the oxidative metabolism of structurally diverse molecules including …

Pyrimidine (imatinib, dasatinib, nilotinib and pazopanib), pyridine (sorafenib) and pyrrole
(sunitinib) tyrosine kinase inhibitors (TKIs) are multi-targeted TKIs with high activity towards …